Lateral Flow Assays Market

The lateral flow assays market is expected to grow from USD 9.14 billion in 2026 to USD 13.52 billion by 2031, with a CAGR of 8.1%. The high prevalence of infectious diseases worldwide and the resulting need for testing, rapid growth in the geriatric population, the rising use of home-based lateral flow assay devices, and growing demand for POC testing are the major factors driving market growth. However, inconsistent accuracy compared with other methods and reluctance among doctors and patients to shift from traditional diagnostics are restraining growth in the lateral flow assays market.

Regulatory requirements, demand for rapid decentralized testing, and continued advances in assay sensitivity, multiplexing, digital interpretation, and scalable manufacturing are shaping the lateral flow assays market. The expansion of testing across infectious diseases, self-testing, women's health, veterinary diagnostics, and other decentralized applications is creating opportunities for manufacturers to broaden their LFA portfolios and develop higher-value formats. Recent industry activity includes Abbott's launch of the Bioline Dengue Duo fingerstick test in Brazil, which detects NS1 antigen and IgM/IgG antibodies in 15–20 minutes, while Sapphiros has developed high-volume visual and digital LFA platforms with manufacturing capacity of up to 5 billion units annually.

To know about the assumptions considered for the study download the pdf brochure

The prominent players in the lateral flow assays market include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), SurModics, Inc. (US), and OraSure Technologies Inc. (US), among others. These companies are pursuing a combination of product launches, manufacturing expansion, strategic partnerships, acquisitions, and technology development to strengthen their positions across rapid and decentralized diagnostics. For example, in January 2024, OraSure invested USD 30 million in Sapphiros and secured distribution rights to products in its pipeline, including next-generation lateral flow technologies. In November 2025, Roche entered a strategic agreement giving it access to at least 1 billion lateral flow tests annually from Sapphiros' UK manufacturing capacity.

Abbott is the leading player in the global lateral flow assays market, accounting for the largest share of the global LFA market in 2025. Its dominance stems from a diverse LFA portfolio spanning infectious disease, cardiac, and consumer diagnostics, supported by continuous innovation. Abbott's strategic investments in reader-enabled and multiplex LFA formats, along with a strong global manufacturing footprint and R&D pipeline, reinforce its leadership position. The company’s focus on benchtop reader integration and pharma/biotech QC applications signals its intent to stay ahead in high-value LFA segments and sustain its competitive advantage.

Roche is a key leader in the lateral flow assay space, accounting for the second-largest share of the global market. Known for its high-sensitivity LFA products, Roche has made strides in digital-read capabilities and advanced sandwich assays targeting infectious diseases and oncology screening. Its regular product refreshes and R&D expansion, including enhanced multiplex LFA formats, reflect its ongoing commitment to innovation. Roche’s established global footprint and investment in smart diagnostic technologies position it as a formidable force in premium LFA segments, strengthening its presence during market transitions.

Danaher commands a significant share of the LFA market. Beyond components, its Life Sciences portfolio, bolstered by acquisitions like Pall and Cytiva, equips Danaher to influence next-generation LFA platforms for process development and QC in biopharma. In 2023, Danaher further solidified its position by acquiring Abcam, strengthening its research-stage diagnostics capabilities. With a strong operational backbone, strategic M&A, and a growing role in supplying membranes, conjugates, and benchtop instruments, Danaher is a key enabler of LFA innovation, powering the ecosystem behind major LFA brands.

Market Ranking

The lateral flow assays (LFA) market is primarily led by Abbott Laboratories (US), F. Hoffmann‑La Roche Ltd. (Switzerland), and Danaher Corporation (US). Together, these companies command the largest share of the global LFA market because of their comprehensive portfolios, ongoing innovation, robust global footprint, and strategic expansion efforts. Abbott Laboratories holds a dominant position in global LFA revenue. Its portfolio spans infectious disease, cardiac, consumer, and veterinary diagnostics, highlighted by innovations like reader-integrated and multiplex assay formats. Abbott’s global manufacturing footprint, ongoing R&D investment, and strategic expansions sustain its lead in high-value LFA applications. F. Hoffmann‑La Roche Ltd. secures the second-largest market share with a reputation for high-sensitivity assays. Its investments in digital-read technologies and advanced sandwich/multiplex LFAs targeting infectious diseases and oncology reflect a sustained emphasis on innovation. A robust global presence and regulatory credentials empower Roche’s position in premium diagnostic segments. Danaher Corporation plays a pivotal role both as a direct LFA provider and a key component enabler, leveraging its Life Sciences segment, including Pall, Cytiva, and Abcam, to support assay development and QC. Danaher’s strategic acquisitions and supply capabilities in membranes, conjugates, and reader instruments have made it a backbone of the LFA ecosystem, supporting biopharma and clinical diagnostics. 

Related Reports:

Lateral Flow Assays Market by Product (Kits, Readers), Application (HIV, HPV, TB, Cardiac Marker, Pregnancy, Hepatitis, Food Safety), Sample (Blood, Urine, Saliva), Technique (Sandwich, Competitive), End User (Hospitals), Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]